RPG LIFE SCIENCES
|
RPG LIFE SCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 53.01 | 40.90 | 31.13 | 24.19 | 17.54 |
| CEPS(Rs) | 63.33 | 50.27 | 40.60 | 34.15 | 27.43 |
| DPS(Rs) | 16.00 | 12.00 | 9.60 | 7.20 | 4.00 |
| Book NAV/Share(Rs) | 226.67 | 186.00 | 154.66 | 130.88 | 106.77 |
| Tax Rate(%) | 25.61 | 26.22 | 29.64 | 25.35 | 20.41 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.70 | 18.66 | 18.18 | 16.87 | 14.57 |
| EBIT Margin(%) | 19.12 | 16.73 | 15.55 | 13.20 | 9.54 |
| Pre Tax Margin(%) | 18.89 | 16.53 | 15.26 | 12.77 | 8.87 |
| PAT Margin (%) | 14.05 | 12.19 | 10.74 | 9.53 | 7.06 |
| Cash Profit Margin (%) | 16.79 | 14.99 | 14.00 | 13.46 | 11.03 |
| Performance Ratios | |||||
| ROA(%) | 18.82 | 17.71 | 15.89 | 14.00 | 11.25 |
| ROE(%) | 25.69 | 24.01 | 21.80 | 20.36 | 17.21 |
| ROCE(%) | 34.96 | 32.92 | 31.46 | 27.27 | 20.35 |
| Asset Turnover(x) | 1.34 | 1.45 | 1.48 | 1.47 | 1.59 |
| Sales/Fixed Asset(x) | 2.83 | 2.73 | 2.61 | 2.37 | 2.44 |
| Working Capital/Sales(x) | 3.73 | 3.44 | 3.78 | 4.36 | 9.52 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.35 | 0.37 | 0.38 | 0.42 | 0.41 |
| Receivable days | 25.32 | 23.17 | 34.41 | 52.52 | 45.38 |
| Inventory Days | 57.35 | 58.57 | 53.79 | 45.64 | 38.91 |
| Payable days | 147.58 | 128.38 | 132.94 | 138.23 | 106.09 |
| Valuation Parameters | |||||
| PER(x) | 28.87 | 17.01 | 17.98 | 16.00 | 9.72 |
| PCE(x) | 24.16 | 13.84 | 13.78 | 11.34 | 6.21 |
| Price/Book(x) | 6.75 | 3.74 | 3.62 | 2.96 | 1.60 |
| Yield(%) | 1.05 | 1.72 | 1.72 | 1.86 | 2.35 |
| EV/Net Sales(x) | 4.29 | 2.13 | 1.94 | 1.54 | 0.78 |
| EV/Core EBITDA(x) | 18.29 | 10.10 | 9.48 | 8.36 | 4.80 |
| EV/EBIT(x) | 20.91 | 11.78 | 11.48 | 10.85 | 7.46 |
| EV/CE(x) | 6.65 | 3.56 | 2.48 | 1.98 | 1.55 |
| M Cap / Sales | 4.35 | 2.24 | 2.10 | 1.65 | 0.75 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.50 | 16.51 | 13.11 | 3.61 | 13.75 |
| Core EBITDA Growth(%) | 25.87 | 20.05 | 25.61 | 17.98 | 72.84 |
| EBIT Growth(%) | 28.49 | 24.47 | 34.69 | 41.21 | 96.94 |
| PAT Growth(%) | 29.60 | 31.39 | 28.70 | 37.88 | 168.36 |
| EPS Growth(%) | 29.60 | 31.39 | 28.70 | 37.88 | 168.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.01 | 0.07 |
| Current Ratio(x) | 2.28 | 2.57 | 2.58 | 2.21 | 1.52 |
| Quick Ratio(x) | 1.50 | 1.64 | 1.55 | 1.47 | 0.96 |
| Interest Cover(x) | 82.83 | 80.72 | 52.89 | 30.93 | 14.21 |
| Total Debt/Mcap(x) | - | - | - | - | 0.04 |
Compare Financial Ratios of peers of RPG LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| RPG LIFE SCIENCES | ₹3,532.2 Cr | -5.6% | 5.3% | 56.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
RPG LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| RPG LIFE SCIENCES | -5.6% |
5.3% |
56.2% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
